Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
Varga C, Robinson M, Gupta V, Hofmeister C, Nooka A, Kaufman J, Dhodapkar M, Lonial S, Borden S, Ferreri C, Paul B, Atrash S, Bhutani M, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes. Blood 2024, 144: 4702-4702. DOI: 10.1182/blood-2024-204388.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaCD34+ cells/kgStem cell collectionStem cell yieldLevine Cancer InstituteNewly diagnosed multiple myeloma patientsStem cell mobilizationCD34+ cellsInduction therapyCell collectionG-CSFNo significant differenceDose of G-CSFISS stage III diseaseTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCancer InstituteHigh-risk cytogeneticsMedian patient ageMRD-negative statusStage III diseaseStem cell harvestWinship Cancer InstituteSignificant differenceIberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)
Joseph N, Kaufman J, Hofmeister C, Gupta V, Burton B, Pruitt R, Nooka A, Dhodapkar M, Lonial S. Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM). Blood 2024, 144: 1983-1983. DOI: 10.1182/blood-2024-210335.Peer-Reviewed Original ResearchSafety run-inProgression free survivalHigh-risk smoldering myelomaSmoldering multiple myelomaSmoldering myelomaMultiple myelomaRun-inHigh-risk smoldering multiple myelomaRisk of progression to myelomaNo dose limiting toxicitiesRate of tumor regressionProgression to myelomaRecurrent grade 3Treatment of intermediate-Grade 3 thrombocytopeniaCycles of therapyDose-limiting toxicityMedian patient ageOverall survival benefitStem cell collectionToxic therapeutic optionsRisk stratification modelTreatment of intermediateRelapsed myelomaCryptococcal meningitisStem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience
Varga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaLevine Cancer InstituteStem cell yieldNewly diagnosed multiple myeloma patientsStem cell collectionStem cell mobilizationInduction therapyG-CSFDose of G-CSFTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCell collectionCancer InstituteCD34+ cells/kgMRD-negative statusMedian patient ageStem cell harvestWinship Cancer InstituteCD34+ cellsGrowth colony-stimulating factorColony-stimulating factorNDMM patientsGoal dosePatient age